Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Fig. 1

Model diagram. PFS, progression-free survival; PPS, post-progression survival; PrePS, pre-progression survival; TFI, treatment-free interval. 1. Modelled using survival function to PFS Kaplan–Meier data; 2. Modelled using survival function to TFI Kaplan–Meier data; 3. Modelled using average duration of second-line treatment; 4. Modelled using survival function to PrePS Kaplan–Meier curve plus general population background mortality data; 5. Modelled using survival function to PPS Kaplan–Meier curve

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us